Researchers Identify Five Cognitive Phenotypes in MS Researchers Identify Five Cognitive Phenotypes in MS
Researchers have identified five cognitive phenotypes among patients with multiple sclerosis, which can help drive tailored rehabilitative strategies, say researchers.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 19, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Pregnancy May Delay MS
FRIDAY, Sept. 18, 2020 -- Pregnancy can delay the onset of multiple sclerosis (MS) by more than three years, researchers report. The international study found those who'd been pregnant had their first MS symptoms an average of 3.3 years later than... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 18, 2020 Category: General Medicine Source Type: news

Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of glatiramer acetate.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 17, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Donald Trump Is Losing On An Issue Voters Care A Lot About. Here ’s How He’s Trying to Change That
With nearly 200,000 Americans dead from COVID-19 and millions more who lost their health insurance when they lost their jobs this year, President Donald Trump tried this week—as he has done throughout his presidency—to change the conversation. On Sunday, the President issued a new executive order aimed at lowering prescription drug prices, an issue dear to many voters, and boasted on Twitter that “prices are coming down FAST.” The reality is more complicated. Trump’s new executive order, which revokes and replaces a different executive order on drug prices that he signed in July, directs the...
Source: TIME: Health - September 17, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized 2020 Election COVID-19 Explainer News Source Type: news

Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton - Wee SK, Ho CY, Tan SL, Ong CH.
We present a case of a lady with progressive ... (Source: SafetyLit)
Source: SafetyLit - September 17, 2020 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Financial Toxicity Common in Patients With Multiple Sclerosis
WEDNESDAY, Sept. 16, 2020 -- For patients with multiple sclerosis (MS), financial toxicity is common and is associated with lifestyle-altering behaviors or care nonadherence, according to a study published online Aug. 18 in the Multiple Sclerosis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 16, 2020 Category: Pharmaceuticals Source Type: news

Many MS Patients Struggle With Finances, Forgo Treatments
TUESDAY, Sept. 15, 2020 -- More than three-quarters of Americans with multiple sclerosis (MS) experience financial difficulties that often prevent them from getting treatment, new research claims. " Our study results demonstrate the high prevalence... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 15, 2020 Category: General Medicine Source Type: news

High Plasma GFAP Level Predicts Disability in Progressive MS High Plasma GFAP Level Predicts Disability in Progressive MS
A high level of glial fibrillary acidic protein (GFAP) in the blood may predict worsening disability in patients with secondary progressive multiple sclerosis (MS), according to investigators.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 14, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Pregnancy delays the onset of multiple sclerosis by more than THREE YEARS
A study on 3,600 women living in the Czech Republic and Australia revealed women who were pregnant developed the condition on average 3.3 years later than their counterparts. (Source: the Mail online | Health)
Source: the Mail online | Health - September 14, 2020 Category: Consumer Health News Source Type: news

Masitinib Impresses in'Nonactive' Progressive MS Masitinib Impresses in'Nonactive' Progressive MS
The drug, with a completely new mechanism of action for multiple sclerosis, slowed disability in nonactive primary and secondary progressive forms of the disease, where there is no current treatment.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 14, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Multiple Sclerosis Prodrome Holds Promise of Earlier Diagnosis Multiple Sclerosis Prodrome Holds Promise of Earlier Diagnosis
There is now no doubt that a prodromal phase of MS exists for several years before the first demyelinating event occurs, latest evidence shows.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 13, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS NfL Blood Biomarker Captures Suboptimal Treatment Response in MS
Measuring levels of neurofilament light chain is an effective way of detecting disease activity and the need to optimize treatment in patients with multiple sclerosis, independent of other measures, a new study shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 12, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

App for MS Aims to Capture Elusive Signals of Progression App for MS Aims to Capture Elusive Signals of Progression
Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS) -- beyond what standard imaging and clinical biomarkers can tell them.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 12, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Exposure to DMT May Delay Disability Accumulation in Primary Progressive MS Exposure to DMT May Delay Disability Accumulation in Primary Progressive MS
For patients with primary progressive multiple sclerosis, longer exposure to disease-modifying therapy may delay the time at which a patient is restricted to a wheelchair.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 12, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Oxford, AstraZeneca COVID-19 vaccine trials resume days after pause
The study had been previously stopped in July for several days after a participant who got the vaccine developed neurological symptoms; it turned out to be an undiagnosed case of multiple sclerosis that was unrelated to the vaccine. (Source: The Economic Times)
Source: The Economic Times - September 12, 2020 Category: Consumer Health News Source Type: news

Smoking Increases Risk of High Plasma NfL Levels in MS Smoking Increases Risk of High Plasma NfL Levels in MS
A study has found that patients with multiple sclerosis who smoke have an increased risk of higher plasma neurofilament light levels (pNfL), which increase disease activity and reduce response to treatment.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Media News - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Investor Update - September 11, 2020 Category: Pharmaceuticals Source Type: news

Lowering Rituximab Dose in Patients With MS Safe, Effective Lowering Rituximab Dose in Patients With MS Safe, Effective
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and stable choice for patients with multiple sclerosis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 10, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Media News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Investor Update - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020
Basel, 3 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) data will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting from 11-13 September 2020.“While conditions of the nervous system are some of the most complex to understand and treat, we are committed to following the science to reduce relapses in NMOSD and slow and eventually stop disease progression in ...
Source: Roche Media News - September 3, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020
Basel, 3 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) data will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting from 11-13 September 2020.“While conditions of the nervous system are some of the most complex to understand and treat, we are committed to following the science to reduce relapses in NMOSD and slow and eventually stop disease progression in ...
Source: Roche Investor Update - September 3, 2020 Category: Pharmaceuticals Source Type: news

Monthly News Roundup - August 2020
Novartis’ Kesimpta Cleared to Treat Multiple Sclerosis The U.S. Food and Drug Administration (FDA) has approved Kesimpta (ofatumumab), a CD20-directed cytolytic IgG1 antibody used to treat relapsing forms of multiple sclerosis (MS) in adults,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2020 Category: Pharmaceuticals Source Type: news

Use of Fitness Trackers May Spur Exercise in Older Adults With MS
MONDAY, Aug. 31, 2020 -- Older adults with multiple sclerosis (MS) who say they use fitness trackers report greater amounts of physical activity, according to a study published online July 31 in the Disability& Health Journal. Stephanie L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2020 Category: Pharmaceuticals Source Type: news

Influence of the environment on cognitive-motor interaction during walking in people living with and without multiple sclerosis - Wajda DA, Zanotto T, Sosnoff JJ.
BACKGROUND: Motor and cognitive impairments are highly prevalent in people with multiple sclerosis (pwMS). The current theoretical frameworks of cognitive-motor interaction (CMI) suggest that the environment can influence both motor and cognitive performan... (Source: SafetyLit)
Source: SafetyLit - August 31, 2020 Category: International Medicine & Public Health Tags: Environmental Issues, Climate, Geophysics Source Type: news

A comparative study of the effects of yoga and clinical Pilates training on walking, cognition, respiratory functions, and quality of life in persons with multiple sclerosis: a quasi-experimental study - Abas ıyanık Z, Yigit P, Özdoğar AT, Kahraman T, Ertekin, Özakbaş S.
OBJECTIVE: The purpose was to investigate the effects of yoga and clinical Pilates training on walking, respiratory muscle strength, cognition, and quality of life and compare the effects of two popular exercise methods in persons with multiple sclerosis (... (Source: SafetyLit)
Source: SafetyLit - August 31, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Risk for Cancer Reduced for Patients With Multiple Sclerosis
Pooled prevalence rates of breast cancer, digestive cancer, skin cancer were 2, 2, and 1 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 28, 2020 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Neurology, Oncology, Journal, Source Type: news

Risk for Cancer Reduced for Patients With Multiple Sclerosis
FRIDAY, Aug. 28, 2020 -- The risk for cancer is reduced among patients with multiple sclerosis (MS), according to a systematic review and meta-analysis published online Aug. 13 in Autoimmunity Reviews. Mahsa Ghajarzadeh, M.D., M.P.H., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2020 Category: Pharmaceuticals Source Type: news

Smoking, High Early-Life BMI Projected to Add to MS Burden
THURSDAY, Aug. 27, 2020 -- The combined estimated multiple sclerosis (MS) population-attributable fractions (PAFs) for smoking and childhood and adolescent high body mass index (BMI) vary from 11 to 14 percent in conservative estimates, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 27, 2020 Category: Pharmaceuticals Source Type: news

About One in Three Multiple Sclerosis Patients Have Migraine
WEDNESDAY, Aug. 26, 2020 -- Internationally, more than three in 10 patients with multiple sclerosis (MS) have migraine, according to a review published in the September issue of the Journal of Clinical Neuroscience. Omid Mirmosayyeb, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 26, 2020 Category: Pharmaceuticals Source Type: news

Obesity in Youth Could Be Big Risk Factor for MS
WEDNESDAY, Aug. 26, 2020 -- High rates of child and teen obesity could play a growing role in people's risk for multiple sclerosis (MS), British researchers say. Prior research has suggested that 53% of MS risk is directly attributable to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 26, 2020 Category: General Medicine Source Type: news

Obese children are more likely to get multiple sclerosis
Experts at Queen Mary University of London and the University of Oxford say that one in ten cases of the condition are linked to people carrying excess weight as a child or teenager. (Source: the Mail online | Health)
Source: the Mail online | Health - August 26, 2020 Category: Consumer Health News Source Type: news

Researchers pursue 'hidden pathology' to explain fatigue in multiple sclerosis
(Brigham and Women's Hospital) In a study published in Neurology Neuroimmunology& Neuroinflammation, investigators from Brigham and Women's Hospital used positron emission technology (PET) imaging to look for brain's immune cells that may become erroneously activated in MS, leading to fatigue. The team describes a potential link to brain inflammation that may help explain the connection between MS and fatigue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 26, 2020 Category: International Medicine & Public Health Source Type: news

Mechanisms identified to restore myelin sheaths after injury or in multiple sclerosis
(Johannes Gutenberg Universitaet Mainz) A research team led by neurobiologist Professor Claire Jacob has identified an important mechanism that can be used to control the restoration of myelin sheaths following traumatic injury and in degenerative diseases. With the insights gained, the researchers were able to regenerate damaged myelin sheaths in mice by treating them with the active substance theophylline, thereby restoring their nerve cell function. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 24, 2020 Category: Biology Source Type: news

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS
The FDA has approved ofatumumab (Kesimpta) as the first self-administered, targeted B-cell therapy for adults with relapsing forms of multiple sclerosis.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 21, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Trunk and foot acceleration variability during walking relates to fall history and clinical disability in persons with multiple sclerosis - Craig JJ, Bruetsch AP, Lynch SG, Huisinga JM.
BACKGROUND: Persons with multiple sclerosis are often at higher risk for falling, but clinical disability scales and fall risk questionnaires are subjective and don't provide specific feedback about why an individual is unstable. The purpose of this study ... (Source: SafetyLit)
Source: SafetyLit - August 20, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis
Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 20, 2020 Category: Drugs & Pharmacology Source Type: news

What Are the First Signs of Multiple Sclerosis
What Are Usually the First Signs of Multiple Sclerosis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 20, 2020 Category: General Medicine Source Type: news

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
A recentanalysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA found that nearly one-third of commercially insured patients taking brand anticoagulants, diabetes or oncology medicines used manufacturer assistance to help pay their cost sharing for one or more prescriptions, along with more than half of patients taking brand HIV medicines and 70% of patients taking brand multiple sclerosis medicines. For many patients facing high out-of-pocket cost burdens, manufacturer cost-sharing assistance prog...
Source: The Catalyst - August 19, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Patient Assistance Programs Out-of-Pocket Costs Medicaid Let's Talk About Cost Source Type: news

Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera(R)
HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of Biogen's Tecfidera® ca... Biopharmaceuticals, Generics, Neurology, Product Launch Mylan, dimethyl fumarate, Tecfidera, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 19, 2020 Category: Pharmaceuticals Source Type: news

Federal study will test combination of remdesivir and multiple sclerosis in coronavirus patients 
Beta interferon is a drug approved to treat multiple sclerosis, has anti-inflammatory properties and has been shown to stop replication of viruses like SARS, and will be tested with remdesivir. (Source: the Mail online | Health)
Source: the Mail online | Health - August 19, 2020 Category: Consumer Health News Source Type: news

Multiple Sclerosis Drug Shows Promise For HIV Prevention And Treatment
Researchers at The George Washington University in D.C. and their colleagues found that a drug called Fingolimod, that is approved for multiple sclerosis treatment, also blocks HIV transmission and infection in human cells. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 13, 2020 Category: Pharmaceuticals Authors: Anuradha Varanasi, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

MS drug may be used to inhibit hiv infection and reduce latent reservoir
(George Washington University) A multiple sclerosis drug may be used to block HIV infection and reduce the latent reservoir, according to research published in PLOS Pathogens by a team at the RGeorge Washington University. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 13, 2020 Category: Infectious Diseases Source Type: news

Multiple sclerosis drug blocks HIV infection and transmission in human immune cells
(PLOS) An immunomodulatory drug called fingolimod, which is approved for the treatment of multiple sclerosis, blocks human immunodeficiency virus (HIV) infection and transmission in human immune cells, according to a study published August 13 in the open-access journal PLOS Pathogens by Postdoctoral Fellow Rachel Resop and Assistant Professor Alberto Bosque of The George Washington University, and colleagues. These preliminary findings suggest that this compound may be a promising novel therapy for HIV treatment and prevention. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 13, 2020 Category: Infectious Diseases Source Type: news

Commercial health plans have increased patients ’ out-of-pocket costs by over 50% in some therapeutic areas
According to a recentIQVIA analysis, commercial health plans have increased patients ’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of the seven therapeutic areas that IQVIA analyzed, including anticoagulants, asthma/COPD, depression, diabetes, HIV, multiple sclerosis and oncology treatments, average patient cost exposu re between 2015 and 2019 saw a 32% increase for depression, a 50% increase for HIV and a 56% increase for anticoagulants. Cost exposure represents the level of cost sharing patients would have paid out of pocket if financial assistance, lik...
Source: The Catalyst - August 13, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Adherence Drug Cost HIV/AIDS Out-of-Pocket Costs Let's Talk About Cost Source Type: news

'Reelin' in a new treatment for multiple sclerosis
(UT Southwestern Medical Center) In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Ofatumumab Phase 3 Multiple Sclerosis Trials Published Ofatumumab Phase 3 Multiple Sclerosis Trials Published
The B-cell depleting drug given by subcutaneous injection showed lower annualized relapse rates and less disability worsening than teriflunomide in the ASCLEPIOS I and II trials.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 6, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news